Why the study?
Do different formulations of enteric-coated aspirin differ in plasma concentrations and platelet aggregation inhibition in healthy adults?
Do different formulations of enteric-coated aspirin differ in plasma concentrations and platelet aggregation inhibition in healthy adults?
Three different enteric-coated aspirin formulations produced similar significant inhibition of platelet aggregation despite different patterns of systemic delivery, though none may be optimal for chronic antiplatelet use.
No takes yet. Share an insight, caveat, or question.
Enteric-coated aspirin formulations yield equivalent platelet inhibition; supports interchangeability in healthy adults but leaves open optimal chronic use in patients.
Brandon et al. (1986) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: